Dr. Ian Harrison BSc (Hons), PhD is the Scientific Communications and Clinical Trials Manager for Ego Pharmaceuticals. Ian joined Ego Pharmaceuticals in 2017, at first splitting his time between the Research and Development laboratory and the Regulatory Affairs department before moving to his current role. Prior to his position at Ego Pharmaceuticals, he spent many years in medical research and academia and has published on a wide variety of topics, from the impact of reactive oxygen species on cancer development to the optimal topical treatment strategies available for atopic dermatitis. Ian holds a PhD in Pharmacology from Monash University.
His area of focus at Ego Pharmaceuticals is the design and implementation of clinical trials, and the development of technical communications, from presentations and regulatory arguments to scientific publications, for all of Egos stakeholders, including healthcare professionals and consumers.
Bachelor of Science with Honours 1st Class: Monash University, Faculty of Science
Doctor of Philosophy (PhD) in Pharmacology: Monash University, Faculty of Medicine, Nursing and Health Sciences
Thesis: Understanding the Biology of Reactive Oxygen Species and Their Link to Prostate Cancer
Australian Postgraduate Award: Issued by Australian Government Department of Education and Training · May 2013
Coso S, Harrison I, Harrison CB, Vinh A, Sobey CG, Drummond GR, Williams ED, Selemidis S. NADPH oxidases as regulators of tumor angiogenesis: current and emerging concepts. Antioxid Redox Signal. 2012 Jun 1;16(11):1229-47. doi: 10.1089/ars.2011.4489. Epub 2012 Mar 23. PMID: 22229841
Harrison IP, Selemidis S. Understanding the biology of reactive oxygen species and their link to cancer: NADPH oxidases as novel pharmacological targets. Clin Exp Pharmacol Physiol. 2014 Aug;41(8):533-42. doi: 10.1111/1440-1681.12238. PMID: 24738947
Hossain MA, Kocan M, Yao ST, Royce SG, Nair VB, Siwek C, Patil NA, Harrison IP, Rosengren KJ, Selemidis S, Summers RJ, Wade JD, Bathgate RAD, Samuel CS. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1. Chem Sci. 2016 Jun 1;7(6):3805-3819. doi:10.1039/c5sc04754d. Epub 2016 Feb 26. PMID: 30155023
Harrison IP, Spada F. Hydrogels for Atopic Dermatitis and Wound Management: A Superior Drug Delivery Vehicle. Pharmaceutics. 2018 Jun 14;10(2):71. doi: 10.3390/pharmaceutics10020071. PMID: 29899219
Harrison IP, Vinh A, Johnson IRD, Luong R, Drummond GR, Sobey CG, Tiganis T, Williams ED, O' Leary JJ, Brooks DA, Selemidis S. NOX2 oxidase expressed in endosomes promotes cell proliferation and prostate tumour development. Oncotarget. 2018 Oct 23;9(83):35378-35393. doi: 10.18632/oncotarget.26237. eCollection 2018 Oct 23. PMID: 30459931
Harrison IP, Spada F. Breaking the Itch-Scratch Cycle: Topical Options for the Management of Chronic Cutaneous Itch in Atopic Dermatitis. Medicines (Basel). 2019 Jul 18;6(3):76. doi: 10.3390/medicines6030076. PMID: 31323753
Spada F, Harrison IP, Barnes TM, Greive KA, Daniels D, Townley JP, Mostafa N, Fong AT, Tong PL, Shumack S. A daily regimen of a ceramide-dominant moisturizing cream and cleanser restores the skin permeability barrier in adults with moderate eczema: A randomized trial. Dermatol Ther. 2021 Jul;34(4):e14970. doi: 10.1111/dth.14970. Epub 2021 May 24. PMID: 33984185
Spada F, Harrison IP, Barnes TM, Greive KA, Daniels D, Townley JP, Mostafa N, Fong AT, Tong PL, Shumack S. Recruitment of adults with moderate eczema for a randomised trial: Comparison of traditional versus modern methods. Australas J Dermatol. 2021 Nov;62(4):e510-e515. doi: 10.1111/ajd.13699. Epub 2021 Sep 3. PMID: 34477217
Barnes TM, Mijaljica D, Townley JP, Spada F, Harrison IP. Vehicles for Drug Delivery and Cosmetic Moisturizers: Review and Comparison. Pharmaceutics. 2021 Nov 26;13(12):2012. doi: 10.3390/pharmaceutics13122012. PMID: 34959294
Mijaljica D, Spada F, Harrison IP. Skin Cleansing without or with Compromise: Soaps and Syndets. Molecules. 2022 Mar 21;27(6):2010. doi: 10.3390/molecules27062010. PMID: 35335373
Mijaljica D, Spada F, Harrison IP. Emerging Trends in the Use of Topical Antifungal-Corticosteroid Combinations. J Fungi (Basel). 2022 Aug 1;8(8):812. doi: 10.3390/jof8080812. PMID: 36012800
Our talented authors and contributors help translate scientific literature into digestible articles so you can stay informed. Find the answers to your skincare questions through our Science Says hub.